Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947856 · ClinicalTrials.gov registry record · Phase 2
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00947856 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 110 participants.
The verdict
NCT00947856, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
Interventions
- DRUG brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00947856
The ClinicalTrials.gov registry entry for NCT00947856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brentuximab vedotin is the first listed.
NCT00947856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00947856 about?
NCT00947856 is a clinical study titled "A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study". This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
What is the current status of trial NCT00947856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2009-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00947856?
The interventions under investigation include: brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT00947856?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.